Donepezil Tartrate Capsule 3 mg

Adult dose

Dosage and administration: Rivastigmine should be administered orally twice daily, in the morning and evening, with meals. ○ Adults: 1. Treatment of mild to moderate Alzheimer-type dementia The initial dose is 3mg of rivastigmine per day. For each patient, the dose should be increased at intervals of at least 2 weeks up to the maximum tolerated dose or the maximum recommended dose of 12mg per day. Since this medication showed greater efficacy at doses of 6mg per day and above in clinical trials, a target dose range of 6~12mg per day is recommended for most patients. Recommended dose titration Administer 1.5mg of this medication twice daily for at least 2 weeks; if well tolerated, the dose may be increased to 3mg twice daily. Further increases may be made to 4.5mg twice daily and, if well tolerated, after at least 2 weeks, to 6mg twice daily. If adverse reactions (e.g., nausea, vomiting, abdominal pain, or loss of appetite) or weight loss occur, one or more doses may be omitted. However, if adverse reactions or weight loss persist, reduce the daily dose to the previous dose that was well tolerated. 2. Treatment of mild to moderate dementia associated with Parkinson's disease In controlled clinical trials in patients with dementia associated with Parkinson's disease, rivastigmine was administered at 3~12mg per day in 2 divided doses. (1.5~6mg per dose was administered twice daily.). The initial dose is 1.5mg of this medication twice daily. At intervals of at least 4 weeks between doses, and according to the patient's tolerability, the dose may be increased successively to 3mg twice daily, then 4.5mg twice daily, and then 6mg twice daily. If adverse reactions (for example, nausea, vomiting, abdominal pain, or loss of appetite), weight gain, or extrapyramidal symptoms (for example, tremor) occur during treatment, temporarily withholding one or more doses may reduce these symptoms. If adverse reactions persist, the daily dose may be temporarily reduced to the previous well-tolerated dose, or discontinuation of treatment may be considered. 3. Maximum recommended dose Administer 6mg of this medication orally twice daily. 4. Reinitiation The incidence and severity of adverse reactions generally increase at higher doses. If treatment is interrupted for 3 days or longer, restart at the lowest daily dose and titrate as described above. ○ Patients with hepatic or renal impairment: 1. Exposure is increased in patients with moderate renal impairment and mild to moderate hepatic impairment, and more adverse reactions may occur. Therefore, take particular care when titrating the dose according to individual tolerability. 2. Do not administer to patients with severe hepatic impairment, as no studies have been conducted in these patients.

Child dose

○ Children: This medication has not been studied in children; therefore, its use in children is not recommended.

This medication contains the active ingredient rivastigmine and should not be administered to certain patient groups. For example, patients with an allergy to this medication's ingredients or severe liver dysfunction, as well as those who experienced skin allergic reactions from the transdermal patch form of this medication, should not use it. Patients with cardiac diseases, peptic ulcer, asthma, urinary retention, seizure, and extrapyramidal disorders should use this medication with caution, as the side effects may be more severe. Nausea, vomiting, and diarrhea, which are gastrointestinal symptoms, may commonly occur when taking this medication, especially at the beginning of treatment or during dosage adjustments. Additionally, neurological side effects such as dizziness, headache, drowsiness, and tremors may also occur. Patients with dementia related to Parkinson's disease may experience symptoms such as tremors or worsening motor function after taking this medication, so they should consult a doctor if these symptoms develop. This medication can interact with other drugs, especially anesthetics, muscle relaxants, cardiac medications, and psychiatric drugs, so it is essential to consult a physician or pharmacist when taking it together with these medications. Pregnant or breastfeeding women should consult an expert before taking this medication, as its safety has not been sufficiently confirmed. It is recommended to avoid taking this medication while breastfeeding. The safety and efficacy of this medication have not been confirmed in children, so its use is not recommended. In case of overdose, symptoms such as vomiting, diarrhea, dizziness, bradycardia, confusion may occur, and in such cases, immediate medical attention should be sought. Antidote treatments such as atropine may be performed if necessary. Lastly, this medication should be stored out of reach of children, and it is safer not to transfer it to other containers.

• Nausea
• vomiting
• dizziness
• headache
• drowsiness
• tremor
• syncope
• convulsions
• extrapyramidal symptoms
• angina

This medication should be stored in a tightly closed container to protect it from air and moisture. It is important to keep the storage temperature between 1°C and 30°C to maintain its effectiveness and safely use it.

Appearance

A hard capsule with a white-to-yellow powder inside, orange-colored on the upper and lower parts.

Package unit

28 capsules/box [14 capsules/PTP × 2]